.Attributes Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin led to boosted progression-free as well as general survival, resulting in FDA approval and a brand new therapy alternative for patients.